A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Small, Eric Jay
Lance, Raymond S.
Redfern, Charles H.
Millard, Frederick E.
Gardner, Thomas A.
Karsh, Lawrence Ivan
Dawson, Nancy Ann
McCoy, Candice
Stubbs, Andrew
DeVries, Todd
dela Rosa, Corazon P.
Sheikh, Nadeem A.
Shore, Neal D.
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
[3] Sharp Clin Oncol Res, San Diego, CA USA
[4] Moores UCSD Canc Ctr, San Diego, CA USA
[5] Urol Indiana Univ Hlth, Indianapolis, IN USA
[6] Urol Ctr Colorado, Denver, CO USA
[7] Georgetown Univ Med Ctr, Washington, DC USA
[8] Dendreon Corp, Seattle, WA USA
[9] Carolina Urol Res Ctr, Myrtle Beach, SC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5047
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Sipuleucel-T in combination with mini-dose ipilimumab for metastatic, castrate-resistant prostate cancer
    Scholz, Mark C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] Androgen receptor (AR) based biomarker association with response to abiraterone acetate/prednisone (AA/P) in metastatic castrate resistant prostate cancer (mCRPC).
    Kohli, Manish
    Wang, Liguo
    Sicotte, Hugues
    Qin, Rui
    Carlson, Rachel
    Eckel-Passow, Jeanette
    Tan, Winston
    Wu, Kevin
    Dehm, Scott
    Eiken, Patrick W.
    Jimenez, Rafael E.
    Cernigliaro, Joseph
    Quevedo, Fernando
    Costello, Brian Addis
    Pitot, Henry Clement
    Moynihan, Timothy J.
    Ho, Thai Huu
    Dronca, Roxana Stefania
    Bryce, Alan Haruo
    Wang, Liewei
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [23] A molecular and clinico-pathological model for predicting abiraterone acetate/prednisone (AA/P) efficacy in metastatic castrate resistant prostate cancer (mCRPC).
    Kohli, Manish
    Qin, Rui
    Wang, Liguo
    Sicotte, Hugues
    Carlson, Rachel
    Tan, Winston
    Jimenez, Rafael E.
    Wang, Liewei
    Eckel-Passow, Jeanette
    Costello, Brian Addis
    Pitot, Henry C.
    Quevedo, Fernando
    Dronca, Roxana Stefania
    Wu, Kevin
    Moynihan, Timothy Jerome
    Thai Huu Ho
    Bryce, Alan Haruo
    Atwell, Thomas D.
    McMenomy, Brendan P.
    Dehm, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] Kinetics of prostate-specific antigen (PSA) as a marker of abiraterone acetate (AA) efficacy in patients (p) with metastatic castrate-resistant prostate cancer (mCRPC)
    Espana Fernandez, S.
    Piulats, J. M.
    Sala, N.
    Velarde, J. M.
    Ferrandiz, U.
    Etxaniz Ulazia, O.
    Heras Lopez, L.
    Barretina Ginesta, M. P.
    Garcia del Muro, X.
    Font, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [25] Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer (mCRPC).
    Sandhu, Gurprataap Singh
    Parikh, Rahul Atul
    Appleman, Leonard Joseph
    Friedland, David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [26] PEAX: Men with metastatic castrate-resistant prostate cancer (mCRPC) treated with either sipuleucel-T (SIP-T), enzalutamide (ENZA) or abiraterone acetate (ABI) undergoing cardiopulmonary exercise testing (CPET).
    Harrison, Michael Roger
    Khouri, Michel
    Armstrong, Andrew J.
    Zhang, Tian
    McNamara, Megan Ann
    Anand, Monika
    Bratt, Ellen
    Hood, Hillary
    Coyne, Brian
    Wu, Yuan
    Healy, Patrick
    George, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [27] Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Nauseef, Jones T.
    Christos, Paul J.
    Thomas, Charlene
    Nordquist, Luke T.
    Sternberg, Cora N.
    Beltran, Himisha
    Guervil, Sabrina
    Galletti, Giuseppe
    Giannakakou, Paraskevi
    Nanus, David M.
    Tagawa, Scott T.
    Molina, Ana M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [28] Correlation of increased eosinophil count following sipuleucel-T treatment with outcome in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
    McNeel, Douglas G.
    Lin, Daniel W.
    Gardner, Thomas
    Sheikh, Nadeem A.
    Whitmore, James Boyd
    Sims, Robert Brownell
    Dreicer, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] Long-term follow-up from STAMP, a phase II trial, evaluating sipuleucel-T and concurrent (CON) vs sequential (SEQ) abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer patients (pts).
    Small, Eric Jay
    Lance, Raymond S.
    Redfern, Charles H.
    Millard, Frederick E.
    Gardner, Thomas A.
    Dawson, Nancy Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [30] Phase II study of prednisone-dexamethasone switch in metastatic castration resistant prostate cancer (mCRPC) patients treated with abiraterone and prednisone (AA plus P)
    Lozano Mejorada, R.
    Romero Laorden, N.
    Jayaram, A.
    Lopez, F.
    Saez, M. I.
    Villatoro, R.
    Montesa, A.
    Moreno, I.
    Ruiz Vico, M.
    Garcia Ferron, M.
    Rogado, J.
    Cendon Florez, Y.
    Nombela Blanco, P.
    Rivera, L.
    Grau, G.
    Cruz Hernandez, J. J.
    Lorente Estelles, D.
    Attard, G.
    Castro Marcos, E.
    Olmos Hidalgo, D.
    ANNALS OF ONCOLOGY, 2017, 28
12345